Sanofi's big plans for Cialis OTC launch run in­to a red light at the FDA

A lit­tle more than 2 years ago, as Sanofi be­gan to re­tool its lag­ging con­sumer di­vi­sion, the then-new CEO Paul Hud­son spot­light­ed some big plans to fi­nal­ly cap­i­tal­ize on their li­cense from Eli Lil­ly for the over-the-counter ver­sion of the erec­tile dys­func­tion drug Cialis.

That eas­i­er-to-ob­tain drug, Hud­son reck­oned, would play a ma­jor role in gain­ing over­sized earn­ings growth as they set up the con­sumer group to work as a stand­alone arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER